It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have lost about 6.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

In my view, such adjustments are totally acceptable, and I shared my reasons - although obviously not directly comparable - ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

Johnson & Johnson MedTech announced that the U.S. Food & Drug Administration has approved the Ottava robotic surgical system ...

GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...